Let us review what the changes were in the rankings of global pharmaceutical market in 2016.
|
Rankings of revenue of global pharmaceutical enterprises in 2016 |
|||
|
Rank |
Company |
Revenue (M $) |
|
|
1 |
Pfizer |
52,800 |
- |
|
2 |
Novartis |
48,518 |
- |
|
3 |
Merck Sharp & Dohme, MSD |
39,807 |
↑2 |
|
4 |
Roche |
39,252 |
↓1 |
|
5 |
GlaxoSmithKline |
37,929 |
↑3 |
|
6 |
Sanofi |
36,128 |
↓2 |
|
7 |
Johnson & Johnson |
33,464 |
- |
|
8 |
Gilead Sciences |
30,390 |
↓2 |
|
9 |
AbbVie |
25,638 |
↑1 |
|
10 |
AstraZeneca |
23,002 |
↓1 |
|
|
|
|
*Revenue is from FR |
Pfizer and Novartis still ranked first and second, and Roche which ranked third in 2015 was surpassed by MSD of which the performance was largely improved in 2016. GSK showed a strong recovery in 2016, moving up 3 positions, with the largest growth; AbbVie also moved up, and surpassed AstraZeneca to rank ninth.
1 Pfizer

2016 operating revenue (M $): 52,800
2016 revenue growth: +8%
Pfizer was still the leader in global pharmaceutical market.
2 Novartis
2016 operating revenue (M $): 48,518
2016 revenue growth: -2%
Novartis was still the second, but its new drug sales growth was offset by the sales decline of its cancer targetin...









(All Rights Reserved)